Immuneering(IMRX)
$3.79-0.06 (-1.56%)
IMRX
Immuneering financials statements
$3.79
At close:-0.06 (-1.56%)
Want to see IMRX full AI Analyst Report?
Immuneering (IMRX) Ratios
694 Followers
Immuneering Ratios
IMRX's free cash flow for Q3 2026 was $-16.80M. For the 2026 fiscal year, IMRX's free cash flow was decreased by $-15.16K and operating cash flow was $-16.79M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 17.50 | 5.28 | 11.35 | 13.50 | 27.04 |
| Quick Ratio | 17.50 | 5.28 | 11.35 | 13.50 | 27.04 |
| Cash Ratio | 12.77 | 4.82 | 7.57 | 9.02 | 13.29 |
| Solvency Ratio | -4.12 | -5.35 | -4.42 | -4.01 | -3.11 |
| Operating Cash Flow Ratio | -4.50 | -7.33 | -6.24 | -5.48 | -5.48 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 162.74M | $ 28.26M | $ 77.08M | $ 96.23M | $ 141.61M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.02 | 0.08 | 0.04 | 0.04 | 0.03 |
| Debt-to-Equity Ratio | 0.02 | 0.10 | 0.05 | 0.04 | 0.03 |
| Debt-to-Capital Ratio | 0.02 | 0.09 | 0.05 | 0.04 | 0.03 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.06 | 1.27 | 1.13 | 1.11 | 1.07 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.09 | 0.14 | 0.16 | 0.18 | 0.20 |
| Net Debt to EBITDA | 2.24 | 0.50 | 0.95 | 1.32 | 2.06 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 50.11% | 44.56% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | -16325.92% | -1629.17% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | -16238.45% | -1621.52% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | -16325.77% | -1629.17% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | -15937.44% | -1627.11% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | -15937.29% | -1612.33% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | -15937.44% | -1612.33% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 99.09% |
| EBT Per EBIT | 94.36% | 95.26% | 91.54% | 97.62% | 99.87% |
| Return on Assets (ROA) | -24.15% | -115.79% | -52.12% | -41.28% | -20.12% |
| Return on Equity (ROE) | -25.64% | -147.48% | -59.03% | -45.98% | -21.50% |
| Return on Capital Employed (ROCE) | -26.76% | -141.72% | -61.66% | -45.27% | -21.04% |
| Return on Invested Capital (ROIC) | -26.71% | -140.66% | -61.46% | -45.12% | -20.81% |
| Return on Tangible Assets | -24.90% | -133.64% | -55.98% | -43.82% | -21.02% |
| Earnings Yield | -19.35% | -92.54% | -25.60% | -39.47% | -7.88% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 25.53 | 8.45 |
| Payables Turnover | 0.45 | 0.00 | 0.00 | 0.05 | 0.83 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.05 | 0.34 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 |
| Cash Conversion Cycle | -805.71 | 0.00 | 0.00 | -7267.50 | -398.20 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 14.30 | 43.18 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 805.71 | 0.00 | 0.00 | 7281.80 | 441.37 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 14.30 | 43.18 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -1.03 | -1.83 | -1.72 | -1.67 | -1.17 |
| Free Cash Flow Per Share | -1.03 | -1.84 | -1.74 | -1.70 | -1.17 |
| Dividend Paid and CapEx Coverage Ratio | -318.82 | -648.01 | -142.87 | -59.40 | -507.53 |
| Capital Expenditure Coverage Ratio | -318.82 | -648.01 | -142.87 | -59.40 | -507.53 |
| Operating Cash Flow Coverage Ratio | -11.86 | -13.21 | -10.97 | -9.11 | -5.75 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | -139.14 | -14.83 |
| Free Cash Flow Yield | -15.71% | -83.51% | -23.61% | -35.04% | -7.26% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -5.18 | -1.08 | -3.91 | -2.53 | -12.69 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 403.77 | 204.62 |
| Price-to-Book (P/B) Ratio | 1.33 | 1.59 | 2.31 | 1.17 | 2.73 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -6.37 | -1.20 | -4.24 | -2.85 | -13.77 |
| Price-to-Operating Cash Flow Ratio | -6.39 | -1.20 | -4.27 | -2.90 | -13.80 |
| Price-to-Earnings Growth (PEG) Ratio | 0.14 | -0.13 | -7.30 | -0.05 | -15.99 |
| Enterprise Value Multiple | -2.96 | -0.53 | -2.65 | -1.17 | -10.56 |
| Enterprise Value | 164.78M | 33.98M | 153.92M | 60.18M | 356.07M |
| EV to EBITDA | -2.96 | -0.53 | -2.65 | -1.17 | -10.56 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 189.87 | 171.19 |
| EV to Free Cash Flow | -3.62 | -0.62 | -3.12 | -1.34 | -11.52 |
| EV to Operating Cash Flow | -3.63 | -0.62 | -3.14 | -1.36 | -11.54 |
| Tangible Book Value Per Share | 4.80 | 1.15 | 2.94 | 3.89 | 5.65 |
| Shareholders’ Equity Per Share | 4.96 | 1.38 | 3.19 | 4.16 | 5.93 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.01 | 0.08 |
| Net Income Per Share | -1.27 | -2.04 | -1.88 | -1.91 | -1.27 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 0.99 |
| Interest Burden | 1.00 | 0.95 | 0.92 | 0.98 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 114.42 | 12.76 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 49.24 | 3.98 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.87 |
| Income Quality | 0.81 | 0.90 | 0.92 | 0.87 | 0.92 |
Currency in USD
